FRX Forest Road Acquisition Corp

NEW YORK, Dec. 18 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) and Mylan Inc. (NYSE:MYL) announced today that the novel beta blocker Bystolic(TM) (nebivolol) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Bystolic is a once daily medication that can be used alone or in combination with other hypertension treatments. Hypertension affects approximately 72 million adults in the U.S. and 65 percent of patients diagnosed with hypertension have not reduced their blood pressure to an acceptable range (blood pressure